BCL2 is a proto‐oncogene regulating cell cycle and apoptosis, and its expression is associated with lymphomagenesis (Vaux et al., 1988) and is a biomarker of worse prognosis in DLBCL (Kawamoto et al., 2016; Perry et al., 2014). Here, BCL2 is linked to diffuse large B-cell lymphoma.